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Summary In this study, we used immunohistochemical and biochemical analysis to show that gp200-MR6, a
200 kDa molecule that is functionally associated with the human interleukin 4 (IL-4) receptor complex, is
expressed at high levels on normal breast epithelial tissues, at lower levels on in situ carcinomas, and that the
expression is lost in the invasive carcinoma of the breast. Furthermore, a preliminary study showed that benign
epithelial hyperplasia of the breast expresses the gp200-MR6 heterogeneously. Two populations of cells have
been observed: MR6 positive and MR6 negative. Interestingly, MR6-positive cells were observed to have
different morphology from those that were MR6 negative; the nuclei of the former were larger and rounded in
shape, whereas the nuclei of the latter were relatively small and oval in shape. In sodium dodecyl sulphate
polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting, monoclonal antibody MR6 detects the
same molecular weight molecule in both normal and transformed tissue, indicating that the molecule is not a
product of a truncated gene. The intensity of the gp200-MR6 bands correlates with the immunohistochemical
data, indicating that the molecule is expressed at high levels in normal tissue and at lower levels in malignant
tissue. These results suggest that analysis of gp200-MR6 expression may be useful in tumour grading and
prognostic evaluation in breast cancer. Moreover, the molecule may be involved early in the process of
tumorigenesis of the breast, in which a loss or a down-regulation of gp200-MR6 could contribute towards
tumour development and progression via an effect on cell growth and differentiation.
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In a study designed to investigate the role of the human
thymic microenvironment in T-cell maturation (De Maagd et
al., 1985), the monoclonal antibody (MAb) MR6 was raised
against human thymic stromal cells. MAb MR6 shows strong
labelling of the cortical epithelium and much weaker labelling
of macrophages, lymphocytes and dendritic cells in frozen
tissue sections of human thymus (Larche et al., 1987).
Immunoelectron microscopy using gold-coupled reagents
showed that the molecule detected by MAb MR6 is localised
on the surface of these cells (von Gaudecker et al., 1996).
Biochemical analysis by immunoprecipitation and Western
blotting using lysates of normal thymus, B- and T-cell lines
and carcinoma tissue yielded a single band of 200 kDa both
under reducing and non-reducing conditions (gp200-MR6;
Mat et al., 1990). In vitro studies have shown that ligation of
gp200-MR6 with MAb MR6 inhibits interleukin 4 (IL-4)-
dependent immunoglobulin class switching to IgE in allergen-
stimulated B cells; IL-4 induced proliferation of cloned T
cells and expansion of the IL-4-dependent Th2 T helper
lymphocyte subset (Larche et al., 1988; Imami et al., 1994).
However, MAb MR6 does not interfere with the binding of
IL-4 to the CD124 ligand-binding chain of the IL-4 receptor
(IL-4R) (Imami et al., manuscript in preparation). These data
therefore indicate that gp200-MR6 is functionally associated
with the IL-4R.
In a preliminary study, investigating the gp200-MR6
expression on non-thymic epithelium, we showed that all of
the 20 tumours analysed, including lung, ovary, colon,
bladder and thyroid, expressed the antigen (Al-Jabaari et
al., 1989). However, further studies revealed that, although
all bladder tumours express the gp200-MR6 molecule, only
approximately 30% of tumours of the breast and lung are
MR6 positive (Mat et al., 1990; Tungekar et al., 1991, 1996).
These data raise the possibility that changes in gp200-MR6
expression may be related to tumour development. In this
study, in order to investigate further the connection between
the gp200-MR6 and tumorigenesis, we have focused on
tumours of the breast.
The normal resting human mammary gland consists of a
branching system of ducts terminating as groups of smaller
ductules (acini). Their walls are formed by an inner layer of
lining epithelium (luminal epithelium) and by an outer layer
of myoepithelium (Figure 1) that is separated from the
connective tissue stroma by a basement membrane. Luminal
epithelial and myoepithelial cells differ from each other in
their morphology and in the expression of certain markers.
Luminal epithelial cells express keratins 7, 8, 18 and 19
(Taylor-Papadimitriou and Lane, 1987; Guelstein et al., 1988;
Rudland and Hughes, 1989). Myoepithelial cells can be
specifically stained with antibodies to smooth muscle actin
(Bussolati et al., 1980) and to CDIO [anti-common acute
lymphoblastic leukaemia antigen (anti-CALLA)] (Mahendran
et al., 1989).
We used these markers for luminal and myoepithelial cells
together with MAb MR6 to analyse the distribution of
gp200-MR6 in normal and hyperplastic tissue samples and a
panel of other markers to study the expression of gp200-MR6
in the hyperplasia cases. Our data indicate that gp200-MR6 is
homogeneously expressed on both luminal and myoepithelial
cells in the normal mammary duct, heterogeneously expressed
in benign hyperplasia, and is down-regulated in invasive
carcinomas of the breast.
Materials and methods
Tissue samples
Since the epitope detected by MAb MR6 cannot be detected
in formalin-fixed paraffin-embedded tissue, fresh frozen tissue
samples were used throughout this study. However, extensive
attempts to retrieve the gp200-MR6, applying commonly
used antigen retrieval methods such as enzymatic treatment,
microwaving and pressure cooking were carried out. Samples
from 75 breast tissues (14 normal, 21 in situ carcinoma, 32
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invasive carcinoma and eight benign hyperplasia samples)
were obtained from the Departments of Medical Oncology
and Histopathology, Charing Cross Hospital, London, and
from the Department of Histopathology, Royal Sussex
County Hospital, Brighton. Paediatric thymus samples were
obtained from children undergoing cardiac surgery at Great
Ormond Street Hospital, London. Samples were snap-frozen
in liquid nitrogen and stored at -70°C until sectioned.
Antibodies
Monoclonal antibody MR6 was produced as a culture
supernatant in our laboratory (De Maagd et al., 1985).
Anti-E-cadherin (HECD-1) and anti-smooth muscle actin
(sm-actin) antibodies were generous gifts from Dr M
Pignatelli, Department of Histopathology, Royal Postgradu-
ate Medical School (RPMS). HMFG1 antibody directed
against a polymorphic epithelial mucin (MUC-1) was a gift
from Professor A Epenetos, Department of Clinical
Oncology, RPMS (Burchell et al., 1983). Anti-cytokeratin
(CKl-LP34), Dako-CD1O (anti-CALLA), Dako-Ki-67 anti-
bodies and the secondary layer peroxidase-conjugated rabbit
anti-mouse immunoglobulin were obtained from Dako
(Copenhagen, Denmark). Anti-IL-4 receptor antibody was
from Genzyme (West Malling, UK). All monoclonal
antibodies used in this study were of IgG, isotype, except
anti-sm-actin, which was IgG2a.
Antigen retrieval
Different approaches were conducted on formalin-fixed,
paraffin-embedded sections of normal and tumour breast
tissues for retrieving the gp200-MR6 molecule. For compar-
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Figure 1 Diagrammatic description of the ultrastructure of a
normal mammary duct showing the relationship between different
layers.
ison, fresh snap-frozen cryostat breast sections were
immunostained in parallel. Anti-cytokeratin Dako-CK 1
antibody was used as a positive control.
Trypsin treatment Dewaxed slides were incubated in a 0.1%
trypsin solution (in 0.1% calcium chloride, pH 7.8) for 10 or
15 min at 37°C and then rinsed with phosphate-buffered
saline (PBS).
Microwave Citrate buffer (0.01 M, pH 6.0) was preheated in
a microwave for 2 min at 750 W. The slides were placed in
the preheated citrate buffer and microwaved for 5, 10 or
15 min at 750 W. After treatment the slides were allowed to
cool and were then rinsed in PBS (Shi et al., 1991).
Pressure cooking Citrate buffer (0.01 M, pH 6.0) filling one-
third of a domestic stainless-steel pressure cooker was
brought to the boil on a hot plate. The dewaxed sections
held in a stainless-steel rack were then lowered quickly into
the boiling buffer and the lid tightly replaced. After
approximately 5 min, when the cooker reached optimum
pressure (103 kPa/1 5 p.s.i.) and the steam started to escape,
the cooker was depressurised and cooled under running
water. The sections were then cooled down in PBS, without
being allowed to dry (Norton et al., 1994).
Immunohistochemical analysis
Samples were analysed by the indirect immunoperoxidase
technique using MAb MR6 and a panel of other
antibodies (Table I). Frozen sections were cut at -30°C
in a cryostat (Bright Instrument Company, UK) at 6 ,im,
mounted on poly-L-lysine-coated multispot slides (Hendley,
Essex, UK), allowed to air dry for 2-24 h and then
acetone fixed for 10 min. Sections were incubated with the
primary antibodies for 1 h. MAb MR6 was used as a neat
culture supernatant and the remaining antibodies were
used at concentrations determined by previous titrations or
as recommended by the manufacturers (Table I). Sections
were then incubated with the secondary peroxidase-
conjugated rabbit anti-mouse antibody, diluted 1:100 in
PBS, for 30 min at room temperature. To prevent any
possible cross-reactivity with endogenous Ig in the human
tissue, 5% (v/v) normal human serum (NHS) was added
to the secondary antibody preparation. Visualisation was
achieved by a final incubation with diaminobenzidine
tetrahydrochloride substrate (DAB; Sigma, UK) at
0.6 mg ml-', with 0.05% hydrogen peroxide added before
use. The sections were then briefly counterstained with
haematoxylin for 1 min and mounted in Kaiser's gelatin-
based mountant. Irrelevant isotype-matched (IgG,) anti-
body or omission of the primary antibody layer was used
as a negative control. Anti-cytokeratin antibody (CKI-
LP34), which reacts with human keratins, was used as
positive control. Sections were scored for the cellular
distribution of immunolabelling and for the intensity of
Table I Antibodies used in this study and their antigens, classes and titrations
Antibodya Specificity Ig Class Dilutions
MR6 Gp200-MR6 IgGI Neat
HECD-1 E-cadherin IgGI Neat
CKI-LP34 Human keratins (6 and 18) IgGI 1:50
Dako-CD10 CALLA IgGi 1:50
Anti-sm-actin Smooth muscle actin IgG2a 1:1000
Anti-IL-4R IL-4 receptor IgGI 1:10
Dako-Ki-67 Nuclear antigens IgGl 1:50
HMFG-1 MUC-1 IgGI 1:40
Peroxidase-conjugated rabbit Ig Mouse IgG Polyclonal 1:100
CALLA, common acute lymphoblastic leukaemia antigen; HECD-1, human epithelium cadherin-l; HMFG-1, human milk fat
globule-1; MUC-1, mucin-1. aAll antibodies used were mouse anti-human monoclonal antibodies except the secondary antibody,
which was a polyclonal peroxidase-conjugated rabbit anti-mouse immunoglobulin.
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labelling rclative to the positive control used ( for no
stainine, + for wecak. + + for moderate anid + + + for
stroing staining). Although subjective, this method has been
showin to give a ligh degree of concordance between
indepcndcnt observers (Luqmani et tl., 1989). Statistical
alnalysis was peIfolrimed usiig the chi-square test.
Ininlnnohisto(heinical anals/IifS
Screening of all breast tissues (normal, benign or malignant)
was carried out by indirect immunoperoxidase technique and
the results scored as: (- ) for no staining at all, ( + ) for weak,
SDS-PAGE (11(1 Xc 1icrni I)lottiltg
Tissuc lysates were derived from frozen sections of the same
samnples as those used for immunohistochemical analysis.
Lysates were prepared from benign hypcrplasia, carcinoma
in sisit and invasive carcinoma of the breast. Lysates from
normal humllall thyruses, in which the gp200-MR6 is found
in abundance, were used as a positive control. Ten sections
(I2nm thick) wCrC cut fi-om each samiiple at -25 C and
placed in prechilled Eppendorf microfuge tubes. Since each
block was pr-epaLr-ed to have approximately the same
dimenisions, this ensuLred that a similar amount of material
was aLnalysed for each tissue sample. Tubes were transferred
to ice and 110 Il of lysis buffer [10 mM Tris/HCl, pH 7.2,
150 mM sodiumii clhloride, 0.5%o Nonidet P-40; (NP-40,
Sigma)], containing 1 mM of protease inhibitor phenyl
methyl sulphoniyl fluoride (PMSF), was added to each
tube. After 15 min, the lysates were centrifuged at
14 000 r.p.m. at 4 C for 5 min. The resulting cell-free
supernatants were collected and mixed with equal volumes
of double strength noon-reducing Laemmli sample buffer
[100/0 (w v) sodiumi dodecyl sulphate (SDS), 10%, (v v)
glycerol, I M Tris HCI pH 6.8, 0.1% bromophenol blue]
aLnd boiled for 2 5 iriin at u00 C. The samples were
allowed to cool for- 5 min, aliquoted and either analysed
immediately or stored at -20 C until required. The
pr-oteins in the lysates were separated using 7.5°/ SDS-
PAGE (Laemiimli, 1970) in a minigel apparatus (Hoefer
Scientific Instrumenits, USA), and then transferred electro-
phoretically (300 mA for 60-90 min) onto a nylon
membrane (Millipore, UK). Unoccupied charged sites on
the membrane wer-e blocked by immersion in 2.5% (w/v)
skiummed milk powder (Marvel, Cadbury Schweppes, UK)
in PBS for 24 h at 4 C. The nylon membrane was then
incubated with MAb MR6 for 60 min with agitation at
room temperature, washed in 0.5% (w/'v) milk powder and
then incubated with peroxidase-conjugated rabbit anti-
mouse Ig [diluted 1:100 in 0.5% (w/v) milk powder] for
45 min with agitation at room temperature. Bands were
visualised by incubating the membrane with DAB/0.05%
hydrogen peroxide lor 10 min, or alternatively, in order to
get a higher senisitivity, by using the enhanced chemilumi-
nescence method (ECL, Amersham, UK).
Results
Anti!en retriei(,Il
Dewaxed, rehydrated, paraffin-embedded breast sections
were treated with trypsin and then stained with MAb
MR6 or anti-cytokeratin antibody. Snap-frozen fresh tissue
sections were stalined with MAb MR6 at the same time as a
control for the effectiveness of the MR6 staining. Anti-
cytokcratin antibody stained the epithelium in the paraffin-
embedded breast tissue sections treated with trypsin, but it
was not possible to obtain any MR6 staining. The frozen
sections did, on the other hand, show a normal MR6
staining pattern. Similalr results were also obtained when
s'amples were treated with microwaving, pressure cooking or
a combination of thesc methods. However, longer periods of
exposure to microwave heat (10 15 min) led to massive
tissue damage and subsequcnt lifting from the slides. The
fact that this antigcn cainnot be detected in formralin-fixed
tissue samples has made it difficult to collect a larger
numiiber of saim,ples of benign hyperplasia of the bre(ast, for
this conditioni is usually diagnosed by chance in tissue
resected for other reasons.
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Figure 2 Percentages of gp200-MR6-positive breast samples
stained with MAb MR6 using immunoperoxidase method, (-)
for no staining, ( + ) for weak. ( + + ) for moderate, aind ( + + + )
for strong staining. (a) Normal. (b) In siltl. (c) Invasive.
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(+ +) for moderate and (+ + +) for strong staining. Anti-
cytokeratin staining was scored as + + + since the intensity of
staining was very strong in all samples studied. The staining
intensity ofthe MAb MR6 was scored relative to that obtained
with the anti-cytokeratin antibody and with the negative
control. MAb MR6 was able to detect the gp200-MR6 on the
ducts in all the normal breast tissue samples studied. The
staining intensity was scored as + + in 86% of the normal
samples, whereas in 7% of the normal samples the staining
intensity was weaker (score +), and in another 7% the staining
was very strong (score + + +) (Figure 2). The staining was
homogeneous on luminal epithelium (Figure 3a, small arrow-
head) and myoepithelium (Figure 3a, large arrowhead; 3b,
a
LP34). In carcinoma in situ samples the expression of gp200-
MR6 was less intense overall, with 67% ofthe samples scoring
+ and only 7% scoring + +. Interestingly, 27% of the cases
were negative (-). In samples of invasive carcinoma the
expression was completely lost in 71% of the cases, 18% were
+ and only 12% were + +. Chi-square analysis revealed that
the proportion of positive-negative samples was significantly
different (P<0.001) in normal tissue, in situ carcinoma and
invasive carcinoma (Table II).
Sections that contained both normal and tumour tissue
made it possible to make a direct comparison between
expression of the gp200-MR6 molecule in normal and
transformed cells. Figure 3c shows strongly stained (+ +)
b
Figure 3 Consecutive breast sections showing a normal mammary duct stained with MAb MR6 (a) and with LP34 (b). (c) MR6-
positive normal ducts (small arrowheads) adjacent to an area of MR6-negative invasive carcinoma cells (large arrowhead). LP34
stains the normal and carcinoma cells equally (d). (e) A heterogeneous staining of a hyperplasia sample with MAb MR6, compared
with the homogeneous staining with LP34 (f). Indirect immunoperoxidase staining; original magnification x 200.
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Amnormal ducts (small arrowheads) located in an area of MR6-
negative invasive carcinoma cells (large arrowhead). LP34
stained both normal and abnormal cells equally (Figure 3d).
In all the eight cases of benign hyperplasia of the breast
studied, unusual heterogeneous expression of gp200-MR6
was observed (Figure 3e). This pattern was seen only in the
hyperplastic inner layer of the duct (luminal epithelium)
where some cells were MR6-positive and others were MR6
MR6-negative. These cells were not stained with antibodies
to CDIO and to sm-actin, but they were strongly and
homogeneously stained with LP34 (Figure 3f) and HMFG-1
(indicating that they were luminal epithelial cells). The outer
layer (myoepithelium, CDIO positive, sm-actin positive) was
homogeneously MR6-positive (Figure 4, large arrowhead).
The MR6-positive luminal epithelial cells were bound
together in a clumpy form and appeared to be linked to
the basal layer (Figure 4, small arrowheads).
Consecutive sections of each tissue were stained with other
antibodies, such as LP34 (Figure 3f), HECD-1 and anti-IL-
4R. All these antibodies stained the hyperplastic ducts
homogeneously, with no negative cells observed. Anti-
smooth muscle actin and Dako-CDIO (anti-CALLA)
antibodies clearly stained the myoepithelial layer, whereas
no staining of the hyperplastic cells was observed. The Ki-67
antibody, which reacts with a nuclear antigen in proliferating
cells during late G,, S, M and G2 phases of the cell cycle, but
not in cells in the resting phase Go (Gerdes et al., 1984),
stained the majority of the MR6-positive cells, and also some
of the MR6-negative cells.
Furthermore, some morphological differences were ob-
served between the MR6-positive and the MR6-negative cells.
Table II The proportion of gp200-MR6-expressing samples
Category, No. ofsamples MR6-positivea (%)
Normal tissue 14 14 100
In situ carcinoma 21 16 76
Invasive carcinoma 32 10 31
aSignificantly different (P<0.001), analysed by chi-square test.
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The nuclei of MR6-positive cells were larger and rounder,
whereas the nuclei of MR6-negative cells were relatively
smaller and oval in shape (Figure 4).
SDS-PAGE and Western blotting
Lysates from normal breast tissue, benign hyperplasia, in situ
carcinoma, or from invasive malignant tissues were run on
SDS-PAGE, followed by transfer to a nylon membrane for
Western blotting. The MAb MR6 detected a molecule of
approximately 200 kDa (sometimes 210 kDa) in all the
different lysates. The same 200 kDa band was detected in a
lysate from a normal human thymus, which was used as a
positive control (Figure 5). The intensity of the bands
detected gave an indication of the amount of gp200-MR6
present in each sample. The normal thymic lysate (HT)
contained the largest quantity of the gp200-MR6 molecule
and invasive carcinoma (IC) of the breast contained the least.
Other samples showed intermediate levels of gp200-MR6,
with normal (NB) expressing levels greater than hyperplasia
(BH), which in turn were greater than carcinoma in situ (IS).
This observation is in agreement with the immunohistochem-
ical data.
Discussion
Previous studies on the expression of the IL-4R-associated
gp200-MR6 molecule have indicated that, while all bladder
tumours express the gp200-MR6 molecule, only approxi-
mately 30% of tumours of the breast, lung and colorectal
tumours are MR6-positive (Al-Jabaari et al., 1989; Mat et al.,
1990; Tungekar et al., 1991,1996). In this -paper we present a
more detailed analysis of both benign and malignant tumours
of the breast. Our data reveal that gp200-MR6 expression is
associated with benign and most in situ tumours, while it is
lost from the majority of invasive carcinomas, thus raising
the possibility that loss of gp200-MR6 may play a role in
tumorigenesis. Interestingly, we also observed heterogeneity
of expression of gp200-MR6 within individual samples of
benign hyperplasia; this correlates with morphological
heterogeneity and may have implications for disease
progression.
In breast cancer, gene amplification and/or overexpression
of certain antigens (such as c-erbB-2, also known as HER-2),
have been associated with metastasis and poor prognosis
(Slamon et al., 1987). The c-erbB-2 oncogene becomes
pathologically activated by a truncation of its extracellular
ligand-binding domain leading to continuous triggering of
cell division (Downward et al., 1984). Abnormal expression
of such molecules can be due to either amplification or
structural alteration of the normal cellular proto-oncogene
encoding the receptor protein, resulting in either an increase
in the number of receptor molecules per cell or in a structural
variant of the receptor (Ullrich et al., 1984). However,
considerable attention in recent years has focused on the
possible role of recessive oncogenes or tumour-suppressor
kDa IC NB IC BH IS HT
Figure 4 Frozen breast section of a hyperplasia sample stained
with MAb MR6, showing the heterogeneous expression of gp200-
MR6. The MR6-positive luminal epithelial cells are bound
together in grape-like clumps, and appear to be linked to the
basal layer (small arrowheads). Notice the morphological
differences between the MR6-positive and the MR6-negative
cells; the nuclei of MR6-positive cells are larger and rounder,
whereas the nuclei of MR6-negative cells are relatively smaller
and oval in shape. Indirect immunoperoxidase staining; original
magnification x 400.
211-
Figure 5 Western blot analysis of tissue lysates from normal
thymus (HT), normal breast (NB), benign hyperplasia (BH), in
situ carcinoma (IS), and from invasive carcinoma samples (IC).
Bands were visualised by using ECL method.
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genes, whose activation, expression or introduction results in
the suppression or inhibition of the tumorigenic phenotype.
For example, the loss of tumour-suppressor gene nm23,
which normally regulates development, has been observed to
be associated with enhanced malignant potential (Steeg et al.,
1988; Bevilacqua et al., 1989).
We have analysed the distribution of the gp200-MR6 in
normal and transformed breast tissue in terms of intensity of
expression and its distribution in different types of breast
tissues. In normal breast tissues, gp200-MR6 is expressed on
both luminal epithelium and myoepithelium (moderate in
86% of cases, strong in 7% of cases). In benign hyperplastic
tissues, the expression of gp200-MR6 was heterogeneously
distributed, with moderate staining (+ +) in some cells and
no staining (-) in others. The gp200-MR6 was weak (+) in
carcinoma in situ tissue samples and absent in the majority
(71%) of invasive tumour samples.
These data raise the possibility that gp200-MR6 may act
as the product of a tumour-suppressor gene. This molecule
has previously been shown to be functionally associated with
the receptor for IL-4 (Larche et al., 1988; Imami et al., 1994);
its anti-tumour effect may therefore be mediated via the
action of IL-4 which itself has been shown to have an anti-
tumour action. Competitive binding of ['251]IL-4 demon-
strated the presence of 2000 high-affinity IL-4 binding sites
per cell on the HT29 colorectal carcinoma cell line (Toi et al.,
1992), and human melanoma and ovarian carcinoma cell
lines also express high-affinity IL-4R. Moreover, IL-4 has
been shown to have an anti-proliferative effect on colorectal
carcinoma cells in vitro (Tepper et al., 1989) and an anti-
tumour effect in vivo in the nude mouse xenograft model
(Lahm et al., 1994). The role, if any, of gp200-MR6 in such
tumour suppression is currently under investigation. How-
ever, our observation that in hyperplasia of the breast the
gp200-MR6 molecule is lost while IL-4R continues to be
expressed is consistent with its proposed tumour-suppression
function.
The immunolabelling of the epithelial hyperplasia samples
showed an interesting differential labelling pattern with MR6-
positive and MR6-negative cell population within a single
tissue. The strange pattern of MR6-positive cells, which was
arranged in grape-like clumps (Figure 4), raised the question
of whether these cells (MR6-positive) originated from the
myoepithelial layer. However, antibodies that are used
routinely to delineate myoepithelium (anti-smooth muscle
actin, CALLA) did not stain these MR6-positive clumps,
instead they defined clearly the myoepithelial and basement
membrane layers, indicating that the stained hyperplastic cells
in the lumen were not myoepithelial. Furthermore, HMFG-1
gave a strong and homogeneous staining of the cells in
question confirming that they were luminal. Carcinoma in
situ, a proliferation of presumably malignant cells, confined
to the mammary ducts with no evidence of invasion through
the basement membrane into the surrounding stroma, is
sometimes mistaken for atypical hyperplasia, which is a non-
malignant proliferation of epithelial cells. The histological
differentiation of pure ductal carcinoma in situ (DCIS) from
atypical ductal hyperplasia (ADH) is usually difficult, and
some cases may create diagnostic disagreement among
histopathologists. It has been found that ADH has a
significant role as a marker for high risk of breast cancer
development. Moderate or severe benign hyperplasia, where
cells show a mild variation of cytological pattern with both
oval and round nuclei, were found to have a slight elevation
of breast cancer risk (Page et al., 1985; Tavassoli and Norris,
1990), and in a recent study it has been found that 17% of
DCIS cases were associated with ADH (Lennington et al.,
1994). In this study we have analysed eight cases of moderate
hyperplasia (five to ten epithelial layers), and two of them
were associated with DCIS components. The heterogeneity in
gp200-MR6 expression that we have observed in hyperplasia,
and the variation in cell morphology, may be helpful as a
prognostic measure, where the increased variation in gp200-
MR6 expression and in cytological pattern may indicate an
increased risk of malignant transformation.
In conclusion, we have shown that, while gp200-MR6 is
expressed on normal epithelial cells, benign tissue and in situ
tumours, it is lost from the invasive carcinomas of the breast.
Moreover, its expression within individual hyperplastic
samples is heterogeneous. Analysis of this molecule may
therefore be useful in tumour grading and prognostic
evaluation. Further, functional studies are required to test
the hypothesis that gp200-MR6 has tumour-suppressive
function and that its loss is a primary cause of tumorigenesis.
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